Genetically modified human myoblasts with eNOS may improve regenerative ability of myogenic stem cells to infarcted heart

Kardiologia Polska

Volumn 71, Issue 10, 2013, Pages 1048-1058

  Janeczek, Agnieszka ^a   Zimna, Agnieszka ^a   Rozwadowska, Natalia ^a   Fraczek, Monika ^a   Kucharzewska, Paulina ^b   Ruciński, Marek ^c   Mietkiewski, Tomasz ^c   Kolanowski, Tomasz ^a   Malcher, Agnieszka ^a   Kurpisz, Maciej ^a  

^a INSTITUTE OF HUMAN GENETICS   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c Voivodship Hospital   (Poland)

Author keywords

Angiogenesis; ENOS; Myoblasts; Regenerative medicine; Stem cells

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; MYOGENIC FACTOR; MYOGENIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA MODIFICATION; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; MYOBLAST; MYOGENIC STEM CELL; NONHUMAN; OXIDATIVE STRESS; PLASMID; REAL TIME POLYMERASE CHAIN REACTION; REGENERATIVE ABILITY; STEM CELL;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; ELECTROPORATION; ENDOTHELIAL CELLS; GENETIC THERAPY; HUMANS; MICE; MYOBLASTS, SKELETAL; MYOBLASTS, SMOOTH MUSCLE; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; REGENERATION; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSFECTION; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84888269272     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP2013.0260     Document Type: Article

References (25)

1. World Health Organisation, Cardiovascular Diseases, Statistics on chronic diseases and risk factors http://www.who.int/topics/cardiovascular-diseases/en/ index.html.
2. Laflamme M, Murry CE. Regenerating the heart. Nat Biotech, 2005;7:845-856.
3. Seidel M, Rozwadowska N, Tomczak K, Kurpisz M. Myoblast preparation for transplantation into injured myocardium. Eur Heart J, 2006; Suppl. H: H8-H15.
4. Menasche P. Skeletal myoblasts and cardiac repair. J Mol Cell Cardiol, 2008;45:545-553.
5. Megeney LA, Rudnicki MA. Determination versus differentiation and the MyoD family of transcription factors. Biochem Cell Biol, 1995;73:723-732.
6. Pownall ME, Gustafsson MK, Emerson ChP. Myogenic regulatory factors and the specification of muscle progenitors in vertebrate embryos. Annu Rev Cell Dev Biol, 2002;18:747-783.
7. Potthoff MJ, Wu H, Arnold MA et al. Olsonl Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. J Clin Invest, 2007;117:2459-2467.
8. Siminiak T, Kalawski R, Fiszer D et al. Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: phase I clinial study with 12 months follow-up. Am Heart J, 2004;148:531-537.
9. Horackova M, Arora R, Chen R et al. Cell transplantation for treatment of acute myocardial infarction: unique capacity for repair by skeletal muscle satellite cells. Am J Physiol Heart Circ Physiol, 2004;287:H1599-H1608.
10. Khan TA, Selke FW, Laham RJ. Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Therapy, 2003;10:285-291.
11. Maulik N, Thirunavukkarasu M. Growth factor/s and cell therapy in myocardial regeneration. J Mol Cell Cardiol, 2008;44:219-227.
12. Becker C, Lacchini S, Muotri AR et al. Skeletal muscle cells expressing VEGF induce capillary formation and reduce cardiac injury in rats. Int J of Cardiol, 2006;113:348-354.
13. Ziche M, Morbidelli L, Masini E et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance PJ Clin Invest, 1994;94:2036-2044.
14. Dimmeler S, Hermann C, Galle J et al. Upregulation of superoxide dismutase and nitric oxide synthase mediates the apoptosis-suppressive effects of shear stress on endothelial cells. Arterioscler Thromb Vasc Biol, 1999;19:656-664.
15. Ziche M, Parenti A, Ledda F et al. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res, 1997;80:845-852.
16. Jozkowicz A, Cooke JP, Guevarab I et al. Genetic augmentation of nitric oxide synthase increases the vascular generation of VEGF. Cardiovasc Res, 2001;51:773-783.
17. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol, 1998;274:H1054-H1058.
18. Kong D, Melo LG, Mangi AA et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation, 2004;109:1769-1775.
19. Mees B, Recalde A, Loinard C et al. Endothelial nitric oxide synthase overexpression restores the efficiency of bone marrow mononuclear cell-based therapy. Am J Pathol, 2011;178:55-60.
20. Kupatt C, Hinkel R, von Brühl ML et al. Endothelial nitric oxide synthase overexpression provides a functionally relevant angiogenic switch in hibernating pig myocardium. J Am Coll Cardiol, 2007;49:1575-1584.
21. Espinos E, Liu JH, Bader CR, Bernheim L. Efficient non-virial DANN mediated gene transfer to human primary myoblasts using electroporation. Neuromusular Disorders, 2001;11:341-349.
22. Cui B, Huang L, Fang Y et al. Transplantation of endothelial progenitor cells overexpressing endothelial nitric oxide synthase enhances inhibition of neointimal hyperplasia and restores endothelium-dependent vasodilatation. Microvascular Res, 2001;81:143-150.
23. Seale P, Rudnicki MA. A new look at the origin, function, and stem-cell status of muscle satellite cells. Developmental Biol, 2000;218:115-124.
24. Menasche P. Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol, 2011;50:258-265.
25. Kaminski KA, Bonda TA, Korecki J, Musial WJ. Oxidative stress and neutrophil activation the two keystones of ischemia/reperfusion injury. Int J Cardiol, 2002;86:41-59.